Trial Profile

A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Varlilumab Patients With Advanced Melanoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CDX 301 (Primary) ; Glembatumumab vedotin (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Varlilumab (Primary)
Indications Malignant melanoma
Focus Adverse reactions; Therapeutic Use
Sponsors Celldex Therapeutics Inc

28 Jan 2019 Results (n=62) assessing safety and efficacy of Glembatumumab Vedotin published in the Cancer.
16 Apr 2018 According to a Celldex Therapeutics media release, status changed from recruiting to discontinued, because based on the data from METRIC study, company has decided to discontinue the glembatumumab vedotin program across all indications.
07 Mar 2018 According to a Celldex Therapeutics media release, enrollment in the glembatumumab vedotin plus checkpoint inhibitor cohort has been completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com